Literature DB >> 33710362

[Long-term treatment concepts for osteoporosis].

Barbara Obermayer-Pietsch1, Ines Fössl2, Hans Peter Dimai2.   

Abstract

The need for a long-term pharmacological treatment of osteoporosis, the problem of potential compliance issues and also potentially severe side effects during the treatment are of central interest not only for patients but also for medical guidelines and prescribers. This review summarizes the current knowledge about the pharmacological substances used and the current scientifically based guidelines and approaches for the long-term use as well as the monitoring and potential treatment changes with a special focus on future developments.

Entities:  

Keywords:  Compliance; Drug-related side effects and adverse reactions; Patient monitoring; Pharmaceuticals; Research and development

Year:  2021        PMID: 33710362     DOI: 10.1007/s00108-021-00993-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  4 in total

Review 1.  Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.

Authors:  Elena Tsourdi; Bente Langdahl; Martine Cohen-Solal; Bérengere Aubry-Rozier; Erik Fink Eriksen; Nuria Guañabens; Barbara Obermayer-Pietsch; Stuart H Ralston; Richard Eastell; M Carola Zillikens
Journal:  Bone       Date:  2017-08-05       Impact factor: 4.398

2.  Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.

Authors:  Howard A Fink; Roderick MacDonald; Mary L Forte; Christina E Rosebush; Kristine E Ensrud; John T Schousboe; Victoria A Nelson; Kristen Ullman; Mary Butler; Carin M Olson; Brent C Taylor; Michelle Brasure; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2019-04-23       Impact factor: 25.391

3.  Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

Authors:  Elena Tsourdi; M Carola Zillikens; Christian Meier; Jean-Jacques Body; Elena Gonzalez Rodriguez; Athanasios D Anastasilakis; Bo Abrahamsen; Eugene McCloskey; Lorenz C Hofbauer; Nuria Guañabens; Barbara Obermayer-Pietsch; Stuart H Ralston; Richard Eastell; Jessica Pepe; Andrea Palermo; Bente Langdahl
Journal:  J Clin Endocrinol Metab       Date:  2020-10-26       Impact factor: 5.958

4.  An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.

Authors:  Nannan Li; Dennis Cornelissen; Stuart Silverman; Daniel Pinto; Lei Si; Ingrid Kremer; Sandrine Bours; Robin de Bot; Annelies Boonen; Silvia Evers; Joop van den Bergh; Jean-Yves Reginster; Mickaël Hiligsmann
Journal:  Pharmacoeconomics       Date:  2020-10-07       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.